Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › liraglutide

liraglutide

20 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of liraglutide

99 trials tracked of liraglutide: 68 in phase 3 or 4 and 35 with published results. The most-cited published study has 7289 citations.

99Trials tracked
68Phase 3 & 4
0Recruiting
35With published results
Phase distribution
Phase 4 17 Phase 3 51 Phase 2 21 Phase 1 6 Other / NA 4
  1. Phase 3 Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Completed · 7,289 cited
  2. Phase 3 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity Completed · 861 cited
  3. Phase 3 Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Completed · 658 cited
  4. Phase 3 Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus Completed · 582 cited
  5. Phase 3 Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes Completed · 401 cited
  6. Phase 3 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed · 362 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes Completed · 345 cited
  2. Phase 3 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes Completed · 329 cited
  3. Phase 4 Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI Completed · 269 cited
  4. Phase 3 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Completed · 249 cited
  5. Phase 4 Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes Completed · 242 cited
  6. Phase 3 Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes Completed · 220 cited
  7. Phase 3 Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting Completed · 190 cited
  8. Phase 3 Individualized Obesity Pharmacotherapy Completed · 187 cited
  9. Phase 4 Impact of Liraglutide 3.0 on Body Fat Distribution Completed · 186 cited
  10. Phase 3 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Completed · 134 cited
  11. Phase 4 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis Completed · 129 cited
  12. Phase 3 Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD. Completed · 121 cited
  13. Phase 4 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed · 80 cited
  14. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Completed · 80 cited
  15. Phase 4 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed · 73 cited
  16. Phase 3 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Completed · 69 cited
  17. Phase 3 Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome Completed · 68 cited
  18. Phase 4 The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study Completed · 53 cited
  19. Phase 4 Liraglutide and Peripheral Artery Disease Completed · 52 cited
  20. Phase 3 LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. Completed · 50 cited
  21. Phase 3 RISE Adult Medication Study Completed · 44 cited
  22. Phase 3 Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus Completed · 44 cited
  23. Phase 4 52 Week Trial of Liraglutide in Type 1 Diabetes Completed · 36 cited
  24. Phase 4 Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin Completed · 35 cited
  25. Phase 3 The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification Completed · 32 cited
  26. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. Completed · 24 cited
  27. Phase 3 A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Completed · 16 cited
  28. Phase 4 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Completed · 10 cited
  29. Phase 3 The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease Completed · 10 cited
  30. Phase 4 Cardiovascular Effects of GLP-1 Receptor Activation Completed
  31. Phase 4 A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Completed
  32. Phase 4 Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes Completed
  33. Phase 4 The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Completed
  34. Phase 4 Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure Completed
  35. Phase 4 Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes Completed
  36. Phase 3 Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D Completed
  37. Phase 3 A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. Completed
  38. Phase 3 Liraglutide In Overweight Patients With Type 1 Diabetes Completed
  39. Phase 3 Liraglutide in Adolescents With Type 1 Diabetes Completed
  40. Phase 3 Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes Completed
  41. Phase 3 Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes Completed
  42. Phase 3 Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin Completed
  43. Phase 3 Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment Completed
  44. Phase 3 Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) Completed

Showing the 50 most-cited and recently-updated of 99 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
Neurology Sys. Review
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
Frontiers Apr 12, 2026
Meta-analysis finds liraglutide improves menstrual frequency and BMI in overweight women with PCOS
OB/GYN & Women's Health Meta-analysis
Meta-analysis finds liraglutide improves menstrual frequency and BMI in overweight women with PCOS A Common Weight Loss Drug May Ease a Hidden Cause of Infertility
A systematic review and meta-analysis of 330 overweight or obese women with PCOS found liraglutide significantly increased menstrual frequen…
A common weight loss drug helps overweight women with PCOS restore regular periods and improve metabolic health.
Apr 12, 2026
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Cardiology
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
medRxiv Apr 9, 2026
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Nutrition & Obesity Medicine Meta-analysis
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Apr 8, 2026
Liraglutide reduces OSA severity in patients with COPD and obesity in exploratory analysis
Diabetes & Endocrinology RCT
Liraglutide reduces OSA severity in patients with COPD and obesity in exploratory analysis Could a weight loss drug help people with COPD breathe easier at night?
A secondary exploratory analysis of a 40-week RCT in 40 patients with COPD and overweight/obesity found liraglutide (3.0 mg) significantly r…
A weight loss drug reduced breathing pauses and oxygen drops for people with COPD and sleep apnea, improving general health while day-time s…
Apr 8, 2026
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
Cardiology Meta-analysis
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
Apr 6, 2026
Short-term liraglutide modulates proteins in obesity, showing weight-independent effects and myostatin suppression
Nutrition & Obesity Medicine RCT
Short-term liraglutide modulates proteins in obesity, showing weight-independent effects and myostatin suppression Could a weight-loss drug work by changing your body's proteins?
A 5-week randomized trial in 20 adults with obesity found liraglutide 3 mg daily modulated 124 proteins, with 85% of effects persisting afte…
A weight-loss drug changed 124 blood proteins in a small study, with 85% of shifts not tied to weight loss, hinting at deeper body-wide effe…
Apr 4, 2026
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Diabetes & Endocrinology Cohort
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…
medRxiv Apr 4, 2026